The new generation biotechnology base Stembio started its activities in the TÜBİTAK MARTEK R&D and Innovation region. İbrahim Özsu, Chairman of Stembio, said that they provide services in the field of stem cell and tissue technologies. Özsu said, “Stembio, which is the first and only hybrid cell and tissue center in Türkiye, will reduce foreign dependency in tissue banking with its state-of-the-art laboratory. With the production of various cellular products, it will provide superiority in clinical use and studies in many areas from cancer vaccines to gene therapy cellular products.”
Biotechnology center Stembio Cord Blood Cell and Tissue Center was established to support the introduction of modern health technologies at the cellular and molecular level to Türkiye, and to support the production and diversification of new information in this field. Stembio, which started its activities in the TÜBİTAK MARTEK R&D and Innovation region, provides services in the fields of cord blood banking, tissue banking, stem cell production and banking, and works in seven sub-sections.
Under the leadership of Prof. Dr. Utku Ateş
İbrahim Özsu, Chairman of the Board of Stembio, said that they have a competent staff and advanced technological infrastructure under the leadership of Prof. Dr. Utku Ateş, Founder Partner & General Medical Director. Özsu said, “Stembio carries out all operations in the same center with its advanced laboratory, and we carry out all our activities in accordance with national and international legislation and as required by world standards. We have the cGMP certificate issued within the scope of the Good Manufacturing Practices Quality Assurance System (GMP) of the European Union. In line with our mission, we will maximize our services without leaving the framework of scientific and ethical values, and offer sustainable and reliable processes while applying advanced technology standards.”
It will excel in clinical studies
Expressing that they are investing in the future of medicine in Türkiye in line with the vision of Stembio, Özsu said that they aim to bring health technologies that develop at the cellular and molecular level to our country. Özsu said, “We provide services in an indoor area of 2000 square meters, of which 800 square meters is a production center, in an environment where all processes are monitored 24/7 with special software. Being the first and only hybrid cell and tissue center in Türkiye, Stembio will reduce foreign dependency in tissue banking with its state-of-the-art laboratory. It will provide superiority in clinical use and studies in many areas from genetic diseases to the improvement of cancer types, from gene therapies to the production of cellular products. We also performed our first cord blood storage procedure. We continue to work to maximize our services by adhering to scientific and ethical values.”
Support for physicians and patients
Prof. Dr. Utku Ateş, Founder Partner & General Medical Director said that they are very happy for the advanced laboratory they have brought to Türkiye. In order to support the treatments applied by their colleagues, they will serve with nearly 40 types of cell and tissue products in their centers, which are licensed and licensed by the Ministry of Health and TITCK and are simultaneously members of the EATCB (European Association of Tissue and Cell Banks). Stating that they will share with the physicians and be a beacon of hope for the patients, Ateş continued his words as follows, “We have structured Stembio under seven sub-units in order to provide better service. Among them; StembioCell; production and banking of cellular therapy products, StemCord; autologous (personal) and allogeneic (donation to the community) cord blood processing and banking, StemTissue; production and banking of human tissue grafts (allografts), StemRegen; Providing services and devices for regenerative applications, StemEst services and products for dermocosmetic and aesthetic applications, StemAnima tissue and cellular treatments for animals, StemGen; there are cellular products used in gene therapies.”